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Abstract:  This  cross-sectional  study  investigated  the  relationship  between  the 
aminolevulinate dehydrogenase (ALAD) genotype and blood lead levels among 101 Japanese 
workers.  Blood  lead  concentration  measurement,  biomarkers,  and  genotyping  were 
performed. The minor allele frequency (MAF) for ALAD (ALAD2) was 0.08. Although the 
blood lead level in the subjects with heterozygous GC genotype was significantly higher than 
those with homozygous GG genotype, there were no significant differences for hemoglobin, 
hematocrit,  serum  and  urinary  ALA  levels  among  genotypes.  ALAD2  genotype  was 
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significantly associated with the blood lead concentration, even in the environmental lead 
exposed subjects. Further confirmation with a large sample size is needed. 
Keywords: ALAD gene; blood lead level; environmentally lead exposure; Japanese. 
 
 
1. Introduction 
 
From the public health  point of view, inorganic lead  exposure has been a serious problem, not only in 
the occupational but also in environmental settings [1].  Lead  toxication can cause many diseases such as 
kidney damage [2,3], reproductive system toxicity [4], hypertension [5], and alterations in cognitive 
development in children, even at low doses [6-8]. 
Estimation of the health risks associated with low-level exposures to lead has important implications 
with  respect  to  its  regulation.  Health-based  guidelines  limiting  occupational  and  environmental 
exposures to lead have become more stringent and are now thought to protect most of population against 
major adverse health effects. Recently the United States Centers for Disease Control and Prevention 
also recommended the reduction of lead concentrations <10 g/dL to prevent lead toxicity for children 
under  6  years  old  [9].  However, genetically susceptible individuals may not be fully protected by 
current regulatory standards, so the discovery of genetic factors that might influence susceptibility to 
lead-induced intoxication could have significant public health ramifications [10]. 
Polymorphisms of the ALAD gene have been associated with the accumulation of lead in the blood, 
bone,  and  internal  organs  [10],  and  might  differentially  predispose  for  psychiatric  symptoms  in 
individuals  exposed  to  lead  [11]. Many reports have suggested that the ALAD2 allele may exert 
protective measures against the neurotoxic effects of lead [12-15]. However, the subjects of these reports 
have typically been occupationally exposed workers, and no firm evidence exists for an association 
between ALAD genotype and susceptibility to lead toxicity under environmental exposure levels. 
The objective of this study examined the relationship between ALAD1,  ALAD2 genotypes and 
blood lead level among workers who were not occupationally exposed to lead. 
 
2. Methodology 
 
2.1. Subjects 
 
We explained this study to Japanese healthy workers from a Japanese chemical industry company 
located in Kanagawa prefecture, and received a written informed consent from each participant. A total 
of 101 healthy workers (73 men and 28 women, after exclusion of those who occupationally handled or 
used to handle lead in their lives)  were subjected to medical examination and genotyping. Among these, Int. J. Environ. Res. Public Health 2009, 6           
     
 
1001 
41 men were engaged in logistics and the rest of them were engaged in office work. The mean age, and 
body mass index (BMI) were 43.4± 11.9 years and 23.4± 4.13 kg/m
2 (mean ±  SD), respectively. 
 
2.2. Basic Characteristics and Blood Measurements 
 
Age and smoking status were self-reported. The medical and occupational histories were established 
by interview. Height, weight, systolic and diastolic blood pressures  were  measured  by  trained  staff 
nurses. BMI was calculated as weight by height square (kg/m
2). 
The blood samples of all participants were taken by trained staff nurses and the withdrawn blood 
samples  were  kept  in  the  plain  tubes  for  examining  fasting  blood  glucose,  serum  lipids  (total 
cholesterol, triglyceride, HDL cholesterol), aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyl transpeptidase (γ-GTP), blood urea nitrogen (BUN), serum creatinine (Cr), 
serum uric acid (UA), blood lead concentration, and biomarkers for lead exposure (serum and urinary 
5-aminolevulinic acid; sALA and uALA, and Zinc protoporphyrin; ZnPP).   
Blood lead concentration was measured by flameless atomic absorption spectrophotometry (Hitachi 
Z-9000) with Zeeman effect background correction.  To determine delta-aminolevulinic acid levels 
(sALA in serum and uALA in urine) and Zinc protoporphyrin (Znpp) in blood, we used a type L-6200 
HPLC (Hitachi, Japan). Using this apparatus, stopped-flow HPLC was applied to determine these 
parameters using a reverse phase column after a simple pretreatment. The highest fluorescent intensity 
was obtained when the pretreated sample was doubly diluted with 100 mM sodium acetate (pH 5.0), and 
the sample (60 μL) was introduced into the condensing coil at a temperature of  98  °C , then 50% 
acetylacetone  in  25%  ethanol  was  added,  followed  by  secondary  mixing  with  10%  formaldehyde 
solution.  The  detection  limit  was  2  μg/L,  which  was  2.5  times  higher  than  that  achievable  by 
conventional  method.  Relative  standard  deviations  of  10  blood  samples  calculated  from  4 
determinations  per  sample  for  1  week  were  within  5%.  Haemoglobin  was  determined  by  the 
cyanomethaemoglobin method. 
 
2.3. Genotyping 
 
The  peripheral  blood  from  all  participants  were  drawn,  and  genotyping  for  the  ALAD 
polymorphism  (a  single  nucleotide  polymorphism  database,  dbSNP  ID:  rs1800435  referenced 
information from NCBI, and the International HapMap Project) was performed by polymerase chain 
reaction (PCR) and the single nucleotide primer extension (SNuPe) methods. The blood was pretreated 
with Ampdirect (SHIMADZU Corporation, Kyoto, Japan), which could eliminate the DNA extraction 
process  and  amplify  the  genomic  DNA  directly  from  the  whole  blood.  PCR  primers  5’  - 
GGCCTCAGTCTTCCCTCCTA -3’ (sense) and 5’ -ACCTCTCCACCTCCCGAGTA -3’ (antisense) as Int. J. Environ. Res. Public Health 2009, 6           
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well  as  two  versions  of  SNuPe  primers  (5’  -  CCACACAGGTATGGTGTGAA  -3’  and  5’ 
-CCACACAGGTACGGTGTGAA -3’) were designed with DNASIS Pro Ver.2.0 (Hitachi Software 
Engineering Co. Ltd., Tokyo, Japan), since there is another SNP site 9-bp upstream of the ALAD1-2 
polymorphism. Then, mixed SNuPe primer (5’ -CCACACAGGTAYGGTGTGAA -3’) was made. The 
PCR reactions began with preheating at 80 °C  for 15 minutes, followed by denaturing at 94 °C  for 4.5 
minutes  and  40  cycles  of  denaturing  at  94  °C   for  30  seconds,  annealing  at  60  °C   for  1  minute, 
extension at 72 °C  for 1 minute, with a final extension at 72 °C  for 7 minutes. We then carried out the 
SNuPe method. The reactions included 25 cycles of denaturing at 94 °C  for 10 seconds, annealing at 
53 °C  for 5 seconds, and extension at 60 °C  for 10 seconds. We analyzed the products by using ABI 
7700 (Amersham Biosciences Corp.). As for genotyping accuracy, we compared the genotyping results 
by SNuPe method as well as conventional RFLP, and the agreement rate was 100% except one, which 
was not determined due to the lack of residual sample. 
 
2.4. Statistical Analysis 
 
All values were shown by mean and Standard deviation (SD) except the value mentioned with the 
Geometric mean (GSD). We compared the mean value of all basic characteristic, clinical, biochemical 
variables including blood lead level between GG and GC genotypes by Student's t-test or 
2 test. The 
mean value of biomarkers for lead exposure between two genotypes of ALAD gene was compared by 
using Student’s t-test. All P value <0.05 was considered as statistical significant. 
 
3. Results and Discussion 
 
Table 1 shows the basic characteristics of occupationally non lead exposed subjects. The mean (SD) 
age of all study participants is 43.4 (11.9) yr. The mean blood lead level of all subjects was 3.38 μg/dL 
and the mean blood lead level of GC genotype was significantly higher than that of GG homozygous 
genotype. Many previous studies have shown that the ALAD genotype was associated with blood lead 
levels  among  environmentally exposed children  and occupationally exposed lead workers [16,17]. 
Subjects with ALAD heterozygous GC, and homozygous CC genotypes were more susceptible to 
increased  blood  lead  levels  than  those  with  the  homozygous  GG  genotype.  ALAD2  carriers  had 
significantly higher blood lead level that ALAD1 homozygous [16-19]. The hypothesis of mechanism 
for lead binding affinity with ALAD2 remained controversial [15,20]. However, some studies found 
no  significant  association  between  ALAD2  carriers  and  blood  lead  level  [21-23].  Although  the 
association result is inconsistent, our study  found the blood lead level in the subjects with heterozygous 
GC genotype was significantly higher than that in those with homozygous GG genotype, even in the 
environmentally same exposed lead condition (i.e. very low lead exposure naturally). Age and smoking Int. J. Environ. Res. Public Health 2009, 6           
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status were not significantly different between GG and GC genotypes in the present study (Table 1), 
where these were known confounding variables for ALAD enzyme activity [24,25]. Furthermore, in 
Figure 1, the prevalence of blood lead levels from 1μg/dL to 5 μg/dL in GG genotype was much higher 
than that in GC genotype, but a 7μg/dL blood lead level was more prevalent in GC than that in GG 
genotype. Even in the all non-occupationally lead exposed participants, the blood lead level was shifted 
from the left to the right in ALAD2 carrier genotype (GC). Our finding is similar to that of the other 
studies [16-19]. 
Table 1. Basic characteristics of non-occupationally lead exposed subjects. 
   
   
   
All non lead exposed 
participants 
(N=101) 
ALAD genotype 
P  GG 
(N=84) 
GC 
(N=17) 
Demographics and Clinical 
Sex (Male/Female)  73/28  61/23  12/5  0.54 
Age (years)  43.4 (11.9)  43.2 (11.9)  44.5 (12.2)  0.68 
Smoking (Yes/No)  55/46  45/39  10/7  0.81 
Height, cm  166.3 (8.3)  166.4 (8.2)  165.5 (9.2)  0.66 
Weight, kg  65.0 (13.7)  65.3 (14.4)  63.8 (9.6)  0.68 
Body mass index, kg/m
2  23.4 (4.1)  23.4 (4.2)  23.3 (3.6)  0.94 
SBP, mmHg  130.2 (18.8)  128.7 (17.4)  137.7 (23.9)  0.15 
DBP, mmHg  78.8 (13.0)  78.3 (12.6)  81.1 (15.1)  0.43 
Complete Blood Counts 
White blood cell count, 10
3/μL  61.2 (14.7)  59.7 (13.8)  68.4 (17.6)  0.02 
Red blood cell count, 10
6/μL  465.6 (41.6)  465.1 (42.2)  468.1 (40.0)  0.79 
Hemoglobin, g/dL  14.4 (1.6)  14.3 (1.6)  14.7 (1.7)  0.37 
Hematocrit, %  43.7 (4.0)  43.6 (4.0)  44.1 (4.3)  0.65 
Platelet count, 10
3/μL  24.9 (4.9)  24.9 (4.6)  25.0 (6.1)  0.94 
Biochemical 
AST/GOT, IU/l 
#  22.2 (1.4)  22.1 (1.4)  22.4 (1.4)  0.90 
ALT/GPT, IU/l 
#  22.7 (1.8)  22.8 (1.9)  22.0 (1.6)  0.81 
γ-GTP, IU/l  34.0 (2.1)  32.8 (2.0  40.9 (2.6)  0.38 Int. J. Environ. Res. Public Health 2009, 6           
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Table 1. Cont. 
Total cholesterol, mg/dL  199.6 (36.3)  196.9 (35.1)  212.8 (40.1)  0.10 
Triglyceride, mg/dL 
#  105.9 (1.8)  105.7 (1.9)  107.1 (1.8)  0.93 
HDL cholesterol, mg/dL 
#  53.4 (1.3)  52.9 (1.3)  55.6 (1.3)  0.45 
Blood urea nitrogen, mg/dL  13.6 (3.5)  13.6 (3.6)  13.5 (2.8)  0.90 
Serum creatinine, mg/dL  0.81 (1.2)  0.81 (1.2)  0.78 (1.2)  0.40 
Serum uric acid, mg/dL  5.34 (1.3)  5.38 (1.3)  5.12 (1.2)  0.45 
Lactate dehydrogenase, IU/l 
#  181.6 (1.1)  180.9 (1.2)  185.2 (1.1)  0.54 
Fasting blood sugar, mg/dL 
#  95.6 (1.2)  96.2 (1.2)  92.8 (1.2)  0.49 
Fasting blood sugar, mg/dL 
#  4.98 (1.1)  4.96 (1.1)  5.09 (1.2)  0.44 
Outcome index 
Blood lead level, μg/dL  3.38 (1.9)  3.18 (1.8)  4.35 (2.4)  0.02 
All values are mean (SD) except the value mentioned with the specific symbol; # Geometric mean (GSD) 
BMI is calculated as weight (kg)/height (m
2) 
SBP: Systolic blood pressure, DBP: Diastolic blood pressure 
AST/GOT:aspartate aminotransferase / glutamic oxaloacetic transaminase. 
ALT/GPT: for alanine aminotransferase / glutamic pyruvic transaminase. 
γ-GTP: gamma-glutamyl transpeptidase 
HDL cholesterol: High density lipoprotein cholesterol 
*Significant P value <0.05 in Student's t-test or 
2 test. 
 
Our study showed that the mean white blood cell count in GC genotype was significantly higher than 
that in GG genotype (Table 1), but Shaik et al.  [23] found no significant association. Exploration of this 
discrepancy  might  be  interesting  in  a  future  longitudinal  study,  although  the  mechanism  of  this 
relationship could not be explained in our recent cross-sectional study. 
The recent study found that the frequency of GG genotype of ALAD was 83.2 %, and that of GC 
genotype of ALAD was 16.8 % in this non-occupationally lead exposed Japanese population. There was 
no  CC  homozygous  genotype  in  this  Japanese  general  population.  The  frequency  distribution  of 
genotype was in Hardy–Weinberg equilibrium. The International HapMap Project, and Kelada et al. 
[15] also reported that ALAD2 allele frequency is high in Caucasian, but low in Asians, including 
Chinese and Japanese, and African populations, and a few or no ALAD2 homozygotes was found in 
such populations. Genotype frequency distribution in the present study was similar with data from the Int. J. Environ. Res. Public Health 2009, 6           
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international HapMap for Japanese. According to this data set, the major allele frequency of ALAD 
(ALAD1) was 0.92 and the minor allele frequency (MAF) for ALAD (ALAD2) was 0.08. Although our 
study population is the non-occupationally  lead exposed subjects, the frequency of MAF was very 
similar to that of the general Japanese population according to the International HapMap Project data, 
as well as the study of Sakai et al. [26] that reported on an high occupational lead exposed subject. Thus 
our  study  not  only  confirmed  the  allele  and  genotype  frequencies  of  ALAD2  even  in  the 
non-occupationally  lead exposed free living Japanese population, but also the ALAD2 allele was rare in 
Japanese population. It seems to be concluded that the ALAD2 allele is rare in Asian populations 
including  a  Taiwanese  population  [15,21].  This  finding  may  at  least  partly  provide  support  for  a 
explanation about that why the blood lead levels in the general population with environmental exposure 
to lead level are lower in Japan and other Asian countries when compared with the European countries 
[27].  
 
Figure 1. Histogram of blood lead in all non-occupationally lead exposed  participants. 
Vertical axis showed number of subjects divided by 10 individual each. Longitudinal axis 
showed concentration of blood lead (g/dl). Vertical bar (light blue) showed GG genotype 
of ALAD gene, and vertical bar (dark blue) showed GC genotype of ALAD gene.   
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Table 2 shows the concentration of biomarkers for lead exposure, in non-occupationally lead exposed 
subjects.  There  were  no  significant  differences  for  serum and  uri nary  ALA,  and  ZnPP  between  the 
subjects  with  GG  and  GC  genotype.   The  hematopoietic  system  is  one  of  the  target  organs  in  lead 
poisoning. One of the most important mechanisms of lead toxicity is its effect on enzymes in the heme 
biosynthetic pathway. The enzyme in the biosynthetic pathway of heme in which the effects of lead are Int. J. Environ. Res. Public Health 2009, 6           
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of the highest clinical interest is ALAD. When ALAD activity is deficient due to lead poisoning, 
erythrocyte synthesis become inhibited and blood hemoglobin concentrations become lower. In the 
second step of heme synthesis, ALAD catalyzes the formation of porphobilinogen from two molecules 
of ALA. ALAD is the most sensitive enzyme to lead in the heme pathway and has a high affinity for the 
metal. Lead binds the enzyme’s SH group, which normally binds zinc, preventing the binding of ALA 
[28]. Because lead effectively inhibits ALAD activity, resulting in accumulation of ALA in blood and 
urine, urinary ALA has also been used as a biomarker for lead exposure or a marker of early biologic 
effect of lead [28,29]. In this study, we did not find any significant differences for blood hemoglobin, 
hematocrit, red blood cell count, ZnPP, and serum and urinary ALA levels between GG, and GC 
genotype of ALAD. These may be explained by the fact that our study  subjects were all adults, and who 
were only exposed to lead environmentally unlike chronically exposed lead workers, and the mean value 
of blood lead level in this study subject with ALAD carrier (GC genotype) was only 4.5 g/dL, which 
was lower than the minimum level for lead poisoning (<10 g/dL for children under 6, recommended 
by CDC [9]). So, these findings might be resulting from the low blood lead levels, which may not induce 
hemopoietic abnormalities and consequently not inhibit ALAD activity, effectively.  
 
Table 2. Biomarkers of lead exposure among non-occupationally lead exposed Japanese. 
Variable  ALAD1 (GG)  ALAD2 (GC)  P 
Blood lead level, μg/dL  3.2 + 0.19  4.4 + 0.58  0.02 
sALA, ng/mL  9.1 + 0.39  10.2 + 0.91  0.28 
uALA, mg/g creatinine  0.85 + 0.05  0.81 + 0.11  0.70 
ZnPP, μM  19.0 + 0.54  21.2 + 1.0  0.05 
Hb, mg/dL  14.3 + 1.6  14.7 + 1.7  0.37 
All value are shown as mean + SD 
sALA: Serum 5-aminolevulinic acid, 
uALA: Urinary 5-aminolevulinic acid 
ZnPP: Zinc protoporphyrin, Hb: Hemoglobin 
 
4. Conclusions 
 
This is the first descriptive report of the association between ALAD2 genotype and blood lead 
levels  among  non-occupationally  lead  exposed  Japanese  subjects,  although  there  were  some 
limitations such as lack of data for alcohol consumption and ALAD activity level. The present findings 
as well as lead toxicity complications will be examined in further longitudinal studies. 
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